App Store Uptodown Introduces a New Premium Subscription Service
Uptodown Turbo has now been officially launched globally. This new subscription service offers unique features for users who want to get the most out of Uptodown app store while directly supporting the project’s sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241007185781/en/
The app store built for privacy, safety and freedom: Subscribe to the service, enjoy exclusive access to premium features and support the project! (Photo: Business Wire)
Uptodown Turbo is the platform’s solution to remain independent as an app marketplace focused on security, privacy, and enhanced user experience—free from traditional advertising and the influence of large platforms. Over 37,000 users pre-registered during the testing phase.
Features and pricing
Suscribers enjoy the following benefits: Ad-free navigation, enhanced security features, profile customization, exclusive avatars, community comments highlighted above standard interactions, and priority support. Additionally, new features will be rolled out in the coming months.
As a bonus, Uptodown Turbo subscribers receive up to an 80% discount when signing up for NordVPN, one of the most efficient and reliable VPN services.
Uptodown Turbo is priced at $2.99/month + regional taxes, with the option subscribe annually for $24.99 —offering a 30% discount compared to the monthly rate.
Still, Uptodown will remain completely free for non-Turbo users, who can continue to enjoy basic services with integrated advertising as before.
A new model for a new stage in the mobile ecosystem
Given the ongoing changes in the online advertising landscape, Uptodown believes that offering a VIP service with exclusive features will allow the platform to maintain its high standards, while avoiding the constraints associated with traditional web monetization models. In the words of Luis Hernandez, Uptodown's CEO: [...] Uptodown Turbo is the first step in changing the way apps are distributed and sourced in the mobile industry. We propose to build a store that is independent, private, secure and focused exclusively on the interests of users and developers. For this to happen, we need to change our relationship with the community and the way traditional stores have historically been funded. [...]
About Uptodown
Uptodown is an app marketplace specializing in Android, founded in 2002 and based in Málaga (Spain). It offers a catalog of more than 300,000 apps, organized into categories and accompanied by reviews and media content created by its editorial team. Over 100 million users download apps each month from both its official website and app. More than 100,000 developers already trust Uptodown to distribute their products. https://en.uptodown.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007185781/en/
Contacts
Press:
Raúl Rosso
raul@uptodown.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volvo Cars and HCLTech Collaborate to Drive Engineering Transformation12.6.2025 15:08:00 EEST | Press release
HCLTech, a leading global technology company, today announced that Volvo Cars has chosen HCLTech as one of its strategic suppliers for engineering services. Volvo Cars has been at the forefront of automotive innovation for many years and has set out to shape the future of mobility with strong ambitions on sustainable growth, as it seeks to offer clients the freedom to move in a personal, sustainable and safe way. Drawing on an established relationship in digital and PLM services, this agreement significantly expands HCLTech’s role to cover the delivery of end-to-end engineering solutions at scale. The strategic collaboration will see the company support Volvo Cars’ engineering future ambitions from its automotive Centre of Excellence in Gothenburg, as well as its global offshore and nearshore delivery centers. “We are proud to broaden our relationship with Volvo Cars at such a pivotal moment in its transformation journey,” said Pankaj Tagra, HCLTech Corporate Vice President, Manufactur
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release
KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom